BridgeBio Pharma (BBIO) Income from Continuing Operations (2018 - 2026)
BridgeBio Pharma (BBIO) posted Income from Continuing Operations of 120026000.0 for Q1 2026, up 38.32% sequentially from 194590000.0 in Q4 2025, and up 1.83% YoY from 117874035.73 in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Income from Continuing Operations for 9 years, with the latest figure at 120026000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 1.83% year-over-year to 120026000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 683311000.0 (down 8.56% YoY) and the FY2025 annual result came in at 732938000.0, down 34.89% from the prior year.
- Income from Continuing Operations climbed to 120026000.0 in Q1 2026 per BBIO's latest filing, from 194590000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 35001000.0 in Q1 2024 and troughed at 267389000.0 in Q4 2024.
- A 5-year average of 154424294.12 and a median of 164254000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 76.34% in 2024, then slumped 249.3% in 2025.
- Over 5 years, Income from Continuing Operations stood at 145130000.0 in 2022, then slumped by 39.39% to 202301000.0 in 2023, then tumbled by 32.17% to 267389000.0 in 2024, then gained by 27.23% to 194590000.0 in 2025, then soared by 38.32% to 120026000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 120026000.0, 194590000.0, and 184937000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -155.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -155.89 Mn |
| Mar 31, 2026 | -118.92 Mn |
| Dec 31, 2025 | -194.59 Mn |
| Sep 30, 2025 | -184.94 Mn |
| Jun 30, 2025 | -183.76 Mn |
| Mar 31, 2025 | -122.50 Mn |
| Dec 31, 2024 | -267.39 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -23.16 Mn |
| Dec 31, 2023 | -192.11 Mn |
| Sep 30, 2023 | -174.21 Mn |
| Jun 30, 2023 | -166.62 Mn |
| Mar 31, 2023 | -145.97 Mn |
| Dec 31, 2022 | -145.13 Mn |
| Sep 30, 2022 | -146.52 Mn |
| Jun 30, 2022 | -100.50 Mn |
| Mar 31, 2022 | -194.27 Mn |
| Dec 31, 2021 | -180.57 Mn |
| Sep 30, 2021 | -160.33 Mn |